GlassScriptPhysician profile
Ira Finegold
NPI 1902982085
$16,553.72
in general payments reported to CMS, 2019-2025
33 companies · $2,524 in 2025
The $2,524 reported for 2025 was more than what 76% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,868 · 2020: $1,727 · 2021: $3,960 · 2022: $2,083 · 2023: $2,126 · 2024: $2,265 · 2025: $2,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,814 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,814.44 |
| Education | $100.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,711.43 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $3,246.78 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genentech USA, INC. | $2,345.36 | 2019-2022 | |
| Genzyme Corporation | $1,799.97 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $920.47 | 2019-2025 | |
| Blueprint Medicines Corporation | $676.95 | 2024-2025 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $514.72 | 2019-2021 | |
| Amgen INC. | $476.64 | 2021-2025 | Tezspire |
| Greer Laboratories, INC. | $390.60 | 2019 | |
| Alk-Abello, INC | $267.36 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $238.20 | 2021-2022 | |
| Kaleo, INC. | $229.53 | 2020-2024 | Auvi-Q |
| Optinose US, INC. | $210.63 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.98 | 2020-2025 | Cuvitru, Hyqvia |
| Covis Pharma Gmbh | $201.07 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $178.71 | 2019-2025 | |
| Pfizer INC. | $172.41 | 2019-2023 | |
| Mylan Specialty L.P. | $147.87 | 2019-2022 | |
| Leo Pharma INC. | $98.17 | 2022-2025 | Adbry |
| Aimmune Therapeutics, INC. | $60.11 | 2021-2022 | |
| Pharming Healthcare, INC. | $57.07 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.94 | 2020-2023 | Spiriva Respimat, Stiolto Respimat |
| Ars Pharmaceuticals Operations, INC. | $44.91 | 2025 | Neffy |
| Incyte Corporation | $44.25 | 2022-2025 | Opzelura |
| Abbott Laboratories | $41.29 | 2019 | |
| Grifols USA, LLC | $35.97 | 2021-2022 | |
| Abbvie INC. | $34.26 | 2023-2024 | |
| Biocryst US Sales Co., LLC | $31.12 | 2022-2024 | Orladeyo |
| Csl Behring | $28.90 | 2023 | Kcentra |
| Organon LLC | $27.20 | 2025 | |
| Uswm, LLC | $27.00 | 2021 | |
| Lilly USA, LLC | $19.13 | 2025 | Ebglyss |
| Galderma Laboratories, L.P. | $16.72 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ira Finegold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.